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BACKGROUND: Pazopanib has shown clinical activity against multiple tumour types and is generally well tolerated. However, isolated
elevations in transaminases and bilirubin have been observed. This study examined polymorphisms in molecules involved in
pharmacokinetic and pharmacodynamic pathways of pazopanib and their association with hepatic dysfunction.
METHODS: Twenty-eight polymorphisms in 11 genes were evaluated in pazopanib-treated renal cell carcinoma patients. An
exploratory analysis was conducted in 116 patients from a phase II study; a replication study was conducted in 130 patients from
a phase III study.
RESULTS: No polymorphisms were associated with alanine aminotransferase elevation. The Gilbert’s uridine-diphosphoglucuronate
glucuronosyltransferase 1A1 (UGT1A1) TA-repeat polymorphism was significantly associated with pazopanib-induced hyper-
bilirubinemia in the phase II study. This association was replicated in the phase III study (Po0.01). Patients with TA6/TA6, TA6/TA7,
and TA7/TA7 genotypes experienced median bilirubin increases of 0.31, 0.37, and 0.71 upper limit of the normal range (ULN),
respectively. Of the 38 patients with hyperbilirubinemia (X1.5 ULN), 32 (84%) were either TA7 homozygotes (n¼18) or TA7
heterozygotes (n¼14). For TA7 homozygotes, the odds ratio (95% CI) for developing hyperbilirubinemia was 13.1 (5.3–32.2)
compared with other genotypes.
CONCLUSIONS: The UGT1A1 polymorphism is frequently associated with pazopanib-induced hyperbilirubinemia. These data suggest
that some instances of isolated hyperbilirubinemia in pazopanib-treated patients are benign manifestations of Gilbert’s syndrome, thus
supporting continuation of pazopanib monotherapy in this setting.
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Pazopanib (Votrient, GlaxoSmithKline), recently approved by the
United States Food and Drug Administration (FDA) for the
treatment of patients with advanced renal cell carcinoma (RCC)
(GlaxoSmithKline, 2009), is an oral angiogenesis inhibitor target-
ing vascular endothelial growth factor receptors-1, -2, and -3;
platelet-derived growth factor receptors-a and -b; and the stem cell
factor receptor, c-kit (Sonpavde and Hutson, 2007). It is currently
under clinical development for the treatment of multiple tumour
types (Altorki et al, 2008; Friedlander et al, 2008; Sleijfer et al,
2009; Taylor et al, 2009; Sternberg et al, 2010). Clinical meaningful
efficacy was observed in pazopanib-treated patients with RCC
(Hutson et al, 2010; Sternberg et al, 2010). The safety profile of
pazopanib was generally acceptable and tolerable. The most
common adverse events were diarrhoea, hypertension, hair colour
changes, nausea, anorexia, and vomiting (Sternberg et al, 2010).
Elevations of liver transaminases were the most common
treatment-emergent laboratory abnormalities (Sternberg et al,
2010). Elevations in alanine aminotransferase (ALT) 43 upper
limit of the normal range (ULN) occurred in 18% of the
pazopanib-treated RCC patients. Isolated elevations of total
bilirubin (TBL) 41.5 ULN were seen in 17% of pazopanib-
treated RCC patients. Elevations in liver enzymes were generally
asymptomatic and reversible and concurrent elevations in both
ALT and bilirubin were rare. As the aetiology and mechanism of
liver enzyme elevation in pazopanib-treated patients remain
unknown, recommended management guideliness are based on
analysis of data from clinical trials.
Treatment-associated elevations in transaminases and bilirubin
have been reported with other tyrosine kinase inhibitors including
sunitinib, lapatinib, and erlotinib (Motzer et al, 2007; Loriot et al,
2008; Ryan et al, 2008), and the incidence varies with agent. It is
possible that these treatment-associated elevations in liver
enzymes observed with tyrosine kinase inhibitors reflect over-
lapping on-target and off-target class effects; however, specific
mechanisms remain to be elucidated. Abnormalities in clinical
liver chemistry measurements are important safety signals for liver
injury and may lead to treatment discontinuation, thereby
compromising the potential treatment benefit to the patient.
Understanding the underlying mechanisms of liver chemistry
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management of these safety signals, and in appropriate circum-
stances, allow patients to benefit from continued anticancer
treatment.
We sought to identify genetic markers in selected candidate
genes involved in pazopanib metabolism and pharmacodynamics
that may predict risk of ALT and/or bilirubin elevation on
treatment. Pazopanib is a substrate for p-glycoprotein and breast
cancer-resistant protein, an inhibitor of the human uptake
transporter OATP1B1, and an inhibitor of uridine-diphosphoglu-
curonate glucuronosyltransferase 1A1 (UGT1A1). It is predomi-
nately metabolised by CYP3A4 with a minor contribution from
CYP2C8 and CYP1A2. Functional polymorphisms in these genes as
well as in pazopanib target genes were evaluated using data from
two clinical studies that evaluated the efficacy and safety of
pazopanib in patients with advanced metastatic RCC (Hutson et al,
2010; Sternberg et al, 2010).
MATERIALS AND METHODS
The protocol and informed consent forms were reviewed and
approved by Institutional Review Boards/Independent Ethics
Committees according to local guidelines. Clinical studies were
conducted in accordance with the Declaration of Helsinki. Written
informed consent for participation in the clinical studies was
obtained from all patients, and an additional informed consent for
pharmacogenetics (PGx) research was obtained for participation in
the genetic study.
Patients
The phase II RCC study (VEG102616, Study 1) had 225
participants (Hutson et al, 2010) and the phase III RCC study
(VEG105192, Study 2) had 435 participants (Sternberg et al, 2010).
All patients from Study 1 and 290 patients from Study 2 received
pazopanib (800mg daily); the remaining 145 patients in Study 2
were randomised to the placebo arm. To minimise the effect of
genetic heterogeneity among ethnic groups on the statistical
analyses, the present PGx analyses were performed using the self-
reported ‘white’ patients of European heritage, which represented
the largest subgroup in each of the clinical studies. There were 156
self-reported white patients in Study 1, of whom 116 provided
written informed consent for genetic research and had sufficient
DNA for genotyping. There were 204 self-reported white patients
in Study 2 who received pazopanib, of whom 130 provided written
informed consent for genetic research and had sufficient DNA for
genotyping. The present PGx analysis population, therefore,
consisted of data from the 116 white patients from Study 1 and
130 white patients from Study 2 who received pazopanib and had
genotypic data for at least one of the genetic markers evaluated
(Figure 1).
Study 1 (exploratory)
225 pazopanib-treated
patients from
VEG102616
69
156 self-reported white
patients
Non-white patients
290 pazopannib-treated
patients from
VEG105192a
86
204 self-reported
white patients
74
130 white patients in
candidate gene analysis
Patients without PGx
consent/DNA
116 white patients in
candidate gene analysis
Patients without log10
maximum or baseline
TBL data
Patients without
UGT1A1 data
112 white patients in
UGT1A1 analysis
236 white patients in
combined analysis
124 white patients in
UGT1A1 analysis
3
3 2
2
a 145 patients from VEG105192 were randomized to the placebo arm.
Study 2 (replication)
40
Figure 1 Patient disposition. Of the 225 pazopanib-treated patients in Study 1 (VEG102616) and the 290 pazopanib-treated patients in Study 2
(VEG105192), 112 and 124 patients, respectively, were included in the UGT1A1 pharmacogenetics (PGx) analysis. These patients were self-reported to be
white, provided consent for the PGx analysis, had sufficient DNA for genotyping and valid genotypic data for the UGT1A1 TA-repeat polymorphism, and had
baseline and on-treatment total bilirubin (TBL) data.
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Alanine aminotransferase and bilirubin measurements were
performed by local institutional laboratories. Both ALT and TBL
values were converted to ULN by dividing the laboratory value by
the institutional ULN. None of the patients from either study had
a baseline ALT level 43 ULN or baseline bilirubin level
41.5 ULN.
Genetic polymorphisms and genotyping
Twenty-eight genetic polymorphisms in 11 genes involved in the
pharmacokinetics and pharmacodynamics of pazopanib were
selected (Table 1). The selection was based on reported associa-
tions or assumed functional changes of the polymorphisms to the
expression or activity of the proteins.
The DNA was extracted from blood using the Qiagen (Valencia,
CA, USA) QiAmp DNA Blood kit. The UGT1A1 TA-repeat
polymorphism (rs8175347) was genotyped using the FDA-
approved Third Wave Invader Assay, which called two alleles:
the TA6 (*1) allele and the TA7 (*28) allele. In the rare instance
when a patient had a TA-repeat number that was not 6 or 7 (o1%),
the genotype call for that patient was treated as missing data. The
remaining polymorphisms were genotyped using Illumina (San
Diego, CA, USA) GoldenGate platform (Fan et al, 2003), a single
base chain extension assay modified by GlaxoSmithKline
(Research Triangle Park, NC, USA) (Taylor et al, 2001), TaqMan
SNP Genotyping assays (Applied Biosystems, Foster City, CA,
USA; Livak et al, 1995), or sequencing.
In vitro UGT1A1 inhibition
The activity of human UGT1A1 was measured in the absence and
presence of pazopanib. Human UGT1A1 Supersomes (BD Gentest,
BD Biosciences, San Jose, CA, USA) were preincubated in duplicate
for 5min at 371C in the presence of the pore-former alamethicin,
the UGT1A1 substrate 7-hydroxy-4-(trifluoromethyl) coumarin
(HFC), and pazopanib concentrations ranging from 0 to 250mM.
At the end of preincubation, the enzymatic reaction was initiated
by adding the cofactor uridine 50-diphosphoglucuronic acid
(UDPGA). The reaction was terminated after an additional
10min by adding acetonitrile/acetic acid (94/6 [v/v]), followed by
centrifugation to sediment-precipitated protein. The production of
the HFC metabolite 4-trifluoromethylumbelliferyl glucuronide
(HFC-gluc) in each supernatant was quantified by HPLC-UV,
and the half-maximal inhibitory concentration (IC50) value for
inhibition of UGT1A1 activity was determined. Incubations
without pazopanib were performed in the presence and absence
of UDPGA to confirm production of the UDPGA-dependent
glucuronide metabolite HFC-gluc. Incubations without probe
substrate (HFC) were performed to determine any potential assay
interference by pazopanib. The IC50 of curcumin, a positive-
control inhibitor, was determined in parallel incubations in which
pazopanib was replaced with appropriate concentrations of
curcumin.
In vitro OATP1B1 inhibition
Inhibition of uptake of the OATP1B1 probe substrate [
3H]-
estradiol 17b-D-glucuronide ([
3H]-EG) by pazopanib was mea-
sured using a stably transfected CHO cell line. The CHO-OATP1B1
cells were cultured to confluency, trypsinised, and seeded into
24-well assay plates (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA) at a density of 70000 cellscm
–2 in Dulbecco’s
Modified Eagle Medium (DMEM) with GlutaMAX, 10% (v/v) foetal
bovine serum, 0.5% (v/v) penicillin/streptomycin 10000 unitsml
–1,
0.1% (v/v) L-proline 50mgml
–1, and 0.7% (v/v) geneticin
50mgml
–1. The cell monolayers were used 2 days after seeding
and induced for at least 24h before use with the addition of DMEM
containing sodium butyrate (final concentration, 5mM). In the
inhibition studies, CHO-OATP1B1 monolayers were preincubated
(371C) for 15–30min in 1ml of Dulbecco’s Phosphate-Buffered
Saline (DPBS) with the appropriate concentration of pazopanib.
Triplicate wells were used for each concentration of test compound.
After removal of preincubation solution, 400ml of DPBS containing
the radiolabelled probe substrate and the appropriate concentra-
tions of pazopanib was added to the wells and the cells were
incubated at 371C for 5min. The solution was then removed and
the wells rinsed rapidly three times using 800ml cold (41C) DPBS
before solubilisation with 500ml of 1% (v/v) Triton X-100. Total
radioactivity was determined by scintillation counting.
Statistical analysis
The data were analysed both as continuous variables in a
quantitative trait analysis (QTA) and as discrete values according
to predefined thresholds in a case–control analysis. All analyses
were performed in SAS version 9.1.3 (SAS Institute, Cary, NC,
USA). The QTA was performed using an analysis of covariance
model to assess the effect of genetic factors on baseline, maximum
on-treatment, and change from baseline (delta) values for ALT and
TBL. In the analyses of maximum on-treatment ALT and
maximum on-treatment TBL, baseline was included in the model
as a covariate. A log10-transformation was performed on the ALT
and TBL values and a rank transformation was performed on the
change-from-baseline values to correct for skewness of the data.
For case–control association analysis, a patient was defined as
an ALT ‘case’ if one or more ALT measurements were X3 ULN
during dosing with pazopanib. A patient was classified as an ALT
‘control’ if all ALT measurements were within the normal range
(p1 ULN). A patient was defined as a TBL ‘case’ if one or more
TBL measurements were X1.5 ULN during exposure to pazo-
panib, and a TBL ‘control’ if all measurements were within the
Table 1 Polymorphisms evaluated in pazopanib-treated white patients
with renal cell carcinoma
Gene Polymorphism rs number Reference
CYP1A2  163C/A rs762551 Han et al (2002)
 729C/T rs12720461 Aklillu et al (2003)
CYP3A4  392A/G rs2740574 Rodriguez-Antona
et al (2005)
CYP3A5 6986A/G rs776746 Wong et al (2004)
27289C/A (T398N) rs28365083 Jounaidi et al (1996)
CYP2C8 805A/T (I269F) rs11572103 Dai et al (2001)
1196A/G (K399R) rs10509681
792C/G (I264M) rs1058930 Bahadur et al (2002)
ABCB1  129T/C rs3213619 Kerb (2006)
1236T/C rs1128503
2677G/T/A (A893S/T) rs2032582
3435C/T rs1045642
ABCG2 34G/A (V12M) rs2231137 Mizuarai et al (2004)
421C/A (Q141K) rs2231142 Morisaki et al (2005)
UGT1A1 TA6/TA7 (*28) rs8175347 Bosma et al (1995)
 3279T/G (*60) rs4148323 Sugatani et al (2002)
211G/A (G71R) (*6) rs4124874 Aono et al (1993)
SLCO1B1 388A/G (N130D) rs2306283 Nozawa et al (2002)
521T/C (V174A) rs4149056
VEGFA  2578C/A rs699947 Schneider et al (2008)
 1498C/T rs833061
11154G/A rs1570360
 634G/C rs2010963
936C/T rs3025039
VEGFR2 889G/A (V297I) rs2305948
1416A/T (Q472H) rs1870377
HIF1a 1772C/T (P582S) rs11549465 Tanimoto et al (2003)
1790G/A (A588T) rs11549467
UGT1A1 polymorphism and pazopanib safety
C-F Xu et al
1373
British Journal of Cancer (2010) 102(9), 1371–1377 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
snormal range (p1 ULN). The effect of a genetic polymorphism
on ALT or TBL was assessed using Fisher’s exact test.
The initial exploratory analysis was performed using data from
the phase II study (Study 1; VEG102616) and the replication
analysis was conducted using data from the phase III study
(Study 2; VEG105192). Correction for multiple tests was not
performed. Instead, a threshold of Po0.01 was used to determine
statistical significance in each study. A marker was ‘replicated’
when it was identified to be statistically significant in Study 1
followed by replication in Study 2. For replicated markers,
a combined analysis using data from both studies was carried
out to evaluate the overall effect.
RESULTS
Demographic and baseline characteristics for patients included in
the present PGx investigation from Study 1 and Study 2 are shown
in Table 2. None of the patients included in the PGx analysis had
a baseline ALT level 43 ULN or baseline bilirubin level 41.5 
ULN. Exploratory analyses of the effects of the 28 genetic
polymorphisms on maximum ALT and bilirubin were first
examined using data from Study 1. None of the markers were
significantly associated with maximum ALT (Po0.01), and three
markers in the UGT1A1 and CYP1A2 loci were significantly
associated with maximum bilirubin (Po0.01). The markers
from the UGT1A1 locus were the TA-repeat polymorphism
(UGT1A1*28) and the –3279T/G polymorphism (UGT1A1*60),
and the marker from the CYP1A2 locus was the –163C/A
polymorphism (Table 1).
Replication analyses of the three significant TBL markers
identified in Study 1 were performed using data from Study 2.
Only the TA-repeat polymorphism from the UGT1A1 gene was
replicated (Po0.01). This polymorphism was not associated with
maximum ALT measurements in either study.
Data from both studies were subsequently combined to
determine the overall effect of the UGT1A1 TA-repeat polymorph-
ism on bilirubin levels. Of the 246 patients included in this PGx
analysis, data for bilirubin and the UGT1A1 TA-repeat marker
were obtained for 236 patients (Figure 1). Of the remaining
10 patients, 5 had missing UGT1A1 genotype data and 5 had
missing log10-transformed maximum or baseline TBL data.
As expected, a significant association between the UGT1A1 TA-
repeat polymorphism and maximum bilirubin was observed
(P¼1.6 10
 6 and P¼1.8 10
 8 for the QTA and case–control
analysis, respectively). The median values of maximum bilirubin
were 0.75 ULN, 0.87 ULN, and 1.40 ULN for patients with the
TA6/TA6, TA6/TA7, and TA7/TA7 genotypes, respectively. More-
over, this polymorphism was significantly associated with bilirubin
increases from baseline (delta) during pazopanib treatment
(P¼4.5 10
 5). The median bilirubin increases were 0.31 ULN,
0.37 ULN, and 0.71 ULN for pazopanib-treated patients with
the TA6/TA6, TA6/TA7, and TA7/TA7 genotypes, respectively.
Thus, the median on-treatment bilirubin increase for TA7
homozygotes was 2.3-fold greater than the increase observed for
the TA6 homozygotes (Figure 2).
Compared with the TA6/TA6 and TA6/TA7 genotypes, the odds
ratio (95% confidence interval), positive predictive value, and
negative predictive value for TA7/TA7 genotype were 13.1
(5.3–32.2), 0.49, and 0.90, respectively. The incidence of hyper-
bilirubinemia was 49% (18 of 37) for patients with the TA7/TA7
genotypes and 12% (14 of 113) for patients with the TA6/TA7
genotypes (Figure 3). In contrast, pazopanib-related incidence of
hyperbilirubinemia was only 7% (6 of 86) for patients with the
TA6/TA6 genotype. Of the 38 cases of TBL elevation, 32 patients
(84%) were either TA7 homozygotes (n¼18, 47%) or TA7
heterozygotes (n¼14, 37%).
The ability of pazopanib to inhibit the two major determinants
of serum bilirubin levels, UGT1A1 and OATP1B1, was measured.
Pazopanib was shown to be a potent inhibitor of UGT1A1 as well
as OATP1B1, with IC50 of 1.2 and 0.79mM, respectively (Figure 4).
DISCUSSION
This study shows that both maximum on-treatment bilirubin
concentration and bilirubin increase from baseline were strongly
associated with the UGT1A1 TA-repeat polymorphism. None of the Table 2 Demographic and baseline characteristics for patients in the
PGx study
Characteristics
Study 1
(n¼116)
Study 2
(n¼130)
Age, mean years (s.d.) 61.1 (10.2) 60.3 (9.1)
Male gender, n (%) 78 (67) 93 (72)
BMI, mean (s.d.) 28.5 (6.4) 27.1 (5.1)
Liver metastases, yes (%) 21 (18)
a 34 (26)
ECOG, n (%)
0 74 (64) 46 (35)
1 42 (36) 84 (65)
MSKCC risk category, n (%)
Favourable 53 (46) 51 (39)
Intermediate 45 (39) 72 (55)
Poor 3 (3) 2 (2)
Unknown 15 (13) 5 (4)
Earlier nephrectomy, n (%) 97 (84) 116 (89)
Baseline ALT   ULN, median
(25th, 75th percentile)
0.5 (0.3, 0.6) 0.4 (0.3, 0.7)
Baseline TBL   ULN, median
(25th, 75th percentile)
0.5 (0.3, 0.6) 0.5 (0.3, 0.6)
Abbreviations: ALT¼alanine aminotransferase; BMI¼body mass index; ECOG
PS¼Eastern Cooperative Oncology Group performance status; MSKCC¼Memorial
Sloan-Kettering Cancer Center; PGx¼pharmacogenetics; s.d.¼standard deviation;
TBL¼total bilirubin; ULN¼upper limit of normal range.
aTwo patients from Study 1
did not have information for baseline liver metastases.
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Figure 2 The distribution of baseline total bilirubin (TBL) and maximum
TBL by UGT1A1 TA-repeat genotype for pazopanib-treated white patients
from both Study 1 and Study 2. The maximum bilirubin value for one
patient who had the TA7/TA7 genotype was truncated from 19  upper
limit of normal (ULN) to 6 ULN for viewing purposes. The number of
patients with each genotype, and the median values for baseline TBL,
maximum TBL, and maximum change-from-baseline (delta) TBL are
provided. The variation in baseline TBL, maximum TBL, and change-from-
baseline TBL by genotype is statistically significant for each end point:
P¼4.0 10
 3, 1.6 10
 6, and 4.5 10
 5, respectively.
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Bilirubin is metabolised by UGT1A1 for elimination. The UGT1A1
genetic variant TA7 is known to cause reduced expression of
UGT1A1 (Bosma et al, 1995), and the TA7/TA7 (*28/*28) genotype
predisposes individuals to Gilbert’s syndrome, a benign form of
episodic jaundice (Bosma et al, 1995; Raijmakers et al, 2000). This
UGT1A1 TA-repeat polymorphism has also been reported to be
associated with hyperbilirubinemia induced by several drugs, such
as tranilast, nilotinib, and indinavir (Zucker et al, 2001; Danoff
et al, 2004; Singer et al, 2007). Pazopanib is a potent inhibitor of
UGT1A1 activity in vitro, with an IC50 of 1.2mM. Thus, this study
suggests that pazopanib-induced hyperbilirubinemia may be the
result of inhibition of UGT1A1 activity combined with genetic
defects of the UGT1A1 gene. This would presumably result in
higher levels of unconjugated hyperbilirubinemia, usually asso-
ciated with a benign clinical course. It is possible that bilirubin
elevation associated with other tyrosine kinase inhibitors such as
sunitinib, lapatinib, and erlotinib may also be related to UGT1A1
genotype. However, to our knowledge, data from genetic
investigations for drug-induced hyperbilirubinemia for these
compounds are not yet available.
We observed that 6 (16%) of the 38 patients who had
isolated hyperbilirubinemia had the TA6/TA6 genotype,
suggesting that additional factors may contribute to bilirubin
elevation in pazopanib-treated patients. Concurrent elevations of
transaminases were not seen in these six patients. A recent
genome-wide association study identified OATP1B1 (alternative
symbol SLCO1B1) as one of the top loci associated with bilirubin
levels (Johnson et al, 2009). Genetic markers in the OATP1B1
gene were also evaluated in this study and were not found to
be associated with pazopanib-related bilirubin elevation. As
pazopanib is also a potent inhibitor of OATP1B1 (in vitro), we
cannot exclude the possibility that pazopanib-induced hyper-
bilirubinemia may be the result of inhibition of both OATP1B1 and
UGT1A1 activity combined with genetic defects of the UGT1A1
gene. The lack of association with genetic markers in the OATP1B1
gene may stem from the fact that pazopanib inhibited hepatic
uptake of bilirubin to the same level in both wild type and
variant forms.
Among the 246 patients evaluated in this study, concurrent
elevation of ALT and bilirubin was observed in one patient
(0.4%). This patient was heterozygous (TA6/TA7) for the UGT1A1
TA-repeat polymorphism and had direct bilirubin of 0.5mgl
–1,
representing 22% of TBL (2.3mgdl
–1). Reduced UGT1A1 activity,
both as a result of pazopanib inhibition of UGT1A1 and the genetic
defect of the UGT1A1 gene, may have contributed to the bilirubin
elevation observed in this patient. Concurrent elevations in ALT
and bilirubin levels after pazopanib treatment could indicate liver
toxicity (Kaplowitz, 2006); therefore, it is important to rule out this
possibility to allow continued treatment. This is particularly
important because continued anticancer treatment may allow for
more favourable clinical outcomes and should be feasible
in patients with benign hyperbilirubinemia, as might be the case
for most pazopanib-treated patients. It follows that, for each
patient, the clinical management of hepatotoxicity needs to
be tailored according to the severity and impact of this adverse
effect on the patient. In addition, the mechanisms involved in the
observed elevation in transaminases and bilirubin should also
be considered.
This study focused on data from trials evaluating pazopanib
monotherapy in patients with RCC. The observed elevation in
ALT or bilirubin levels was not associated with liver metastasis for
patients included in the present PGx analysis. The full implications
of these findings for regimens combining pazopanib with other
agents are currently unknown. Clearly, it is important for
clinicians to be aware of potential drug–drug interactions,
particularly with compounds known to be metabolised and
eliminated predominantly through the UGT1A1 pathway. There-
fore, concomitant administration of pazopanib and UGT1A1
substrates that have narrow therapeutic index should be
undertaken with caution. Pazopanib itself is not known to be
subject to significant glucuronidation by UGT1A1. It is, there-
fore, unlikely that defective UGT1A1 would have a direct impact
on the exposure of pazopanib and, therefore, exposure-related
toxicities.
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Figure 4 Pazopanib inhibition of UGT1A1 (A, duplicate data points) and OATP1B1 (B, triplicates). EG, the OATP1B1 probe substrate [
3H]-estradiol
17b-D-glucuronide; IC50, half-maximal inhibitory concentration.
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Figure 3 Cumulative incidence of hyperbilirubinemia (X1.5  upper
limit of normal [ULN]) by UGT1A1 TA-repeat genotype for pazopanib-
treated white patients from both Study 1 and Study 2. The cumulative
incidence of total bilirubin (TBL) X1.5 ULN for each genotype group at
a time point (weeks) is the proportion of patients from the group who had
at least one on-treatment TBL value of 1.5 ULN or greater on or before
the time point.
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recognise that isolated hyperbilirubinemia in pazopanib-treated
patients, after exclusion of other causes such as haemolysis, seems
to have a benign aetiology. Given the life-threatening nature of
cancer and the benign clinical course of unconjugated hyper-
bilirubinemia, the data do not call for population-based prospec-
tive UGT1A1 screening to exclude patients from pazopanib
monotherapy. Bilirubin fractionation should be conducted in
patients who develop hyperbilirubinemia during pazopanib
treatment, which could distinguish unconjugated hyperbilirubine-
mia from conjugated hyperbilirubinemia. The latter would require
further investigation. This may help to elucidate the nature of the
bilirubin elevation and might enable differentiation of the risk of
progression of drug-induced liver injury. A limitation of this study
is the lack of bilirubin fractionation data to allow full assessment
between the UGT1A1 polymorphism and unconjugated bilirubin
levels.
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